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Title	
	
Morphological	 characterisation	 of	 BRAF	 mutated	 melanomas	 by	 means	 of	
immunohistochemistry,	dermoscopy	and	reflectance	confocal	microscopy	
	
Introduction	
	
Melanoma	 is	 the	 most	 lethal	 cutaneous	 malignancy,	 with	 increasing	 incidence	 rate	 in	 the	
general	population,	even	at	young	age.(1,	2)	When	diagnosed	in	early	stage,	surgical	excision	
with	 safety	 margins	 according	 to	 valid	 guidelines	 is	 usually	 curative.	 However,	 its	 early	
invasiveness	 and	 high	 frequency	 of	 genomic	 alterations	 make	 early	 metastatic	 spreading	
common	especially	in	thicker	high	risk	tumors.	Luckily,	the	therapeutic	scenario	of	advanced	
unresectable	 and	 metastatic	 melanoma	 underwent	 striking	 changes	 in	 the	 last	 few	 years,	
thanks	to	the	approval	of	new	molecular	targeted	therapies	and	immunotherapies.	Between	
the	 Seventies	 and	 2011,	 the	 only	 available	 treatment	 was	 Dacarbazine	 chemotherapy,	
followed	 by	 IL-2,	 however	 no	 randomized	 controlled	 trial	 had	 reported	 a	 significant	
improvement	in	survival	rates.(3,	4)	The	advent	of	anti-CTLA4	Antibody	Ipilimumab,	followed	
by	 anti-BRAF	 and	 anti-MEK	 molecular	 targeted	 therapies	 and	 anti-PD1	 antibodies	
dramatically	 improved	 life	 expectancy	 of	 patients	with	 advanced	 and	metastatic	melanoma	
from	an	average	9	months	 to	an	as	yet	undefined	 timeframe.(5,	6)	 	Recently,	5-year	overall	
survival	 rates	 of	 up	 to	 55%	 under	 the	 combined	 molecular	 targeted	 therapies	
Dabrafenib/Trametinib	 and	 of	 up	 to	 60%	 under	 the	 immune-checkpoint	 inhibitors	
Nivolumab/Ipilimumab	have	been	reported.(6)	
One	 of	 the	 main	 milestones	 for	 the	 development	 of	 new	 melanoma	 therapies	 was	 the	
identification	 of	 the	 significant	 role	 of	 the	MAP-Kinases	 signalling	 pathway	 (identified	with	
the	 cascade	 of	 RAS,	 RAF,	 MEK	 and	 ERK)	 leading	 to	 increased	 survival	 of	 malignant	
melanocytic	 cells	 through	 their	 unrestrained	 proliferation	 (7)	 Estimated	 40-60%	 of	
	 7	
melanomas	 harbour	 a	 BRAF	 mutation,	 most	 of	 them	 V600E	 (ca.	 75%),	 a	 substitution	 of	
glutamic	 acid	 for	 valine	 at	 codon	 600.	 The	 most	 frequent	 non-V600E	 mutation	 is	 BRAF-
V600K,	corresponding	to	a	Leucine	substituting	a	Valine	at	codon	600	(15–20%).	More	rarely	
occurring	mutations	are	BRAF-V600D,	BRAF-V600R	and	BRAF-V600M		(1–2%).(8-10)	
BRAF	mutated	melanomas	are	eligible	for	a	molecular-targeted	therapy	using	so	called	“BRAF	
inhibitor	 drugs”	 including	 Dabrafenib,	 Vemurafenib	 and	 Encorafenib,	 nowadays	 mostly	
combined	 with	 a	 “MEK	 inhibitor	 drug”	 such	 as	 Trametinib,	 Cobimetinib	 or	 Binimetinib,	 in	
order	to	reduce	side	effects	and	to	avoid	mechanisms	of	resistance.	In	2018,	the	combination	
of	 Dabrafenib	 and	 Trametinib	 has	 also	 been	 approved	 in	 an	 adjuvant	 setting	 for	 stage	 III	
melanoma.(6,	11-13)	
Interestingly,	BRAF-V600K	mutated	melanomas	seem	to	be	less	responsive	to	BRAF	inhibitor	
therapy,	compared	to	their	BRAF-V600E	mutated	counterparts.	
BRAF	inhibitors	were	the	first	effective	molecular	targeted	therapy	for	malignant	melanoma.	
For	this	reason,	mutational	profiling	has	become	of	outmost	importance	to	establish	from	the	
very	 beginning	 the	 best	 treatment	 options	 in	 patients	 with	 advanced	 melanoma.	 Current	
guidelines	 recommend	 testing	 every	 advanced	 melanoma	 (in	 the	 German	 guidelines	 from	
stage	IIIB)	for	BRAF	mutation,	since	BRAF	inhibitors	are	available	for	both,	the	adjuvant	and	
therapeutic	 setting(14).	 Mutation	 testing	 is	 performed	 on	 primary	 (and	 eventually	 also	
metastatic)	tumour	tissue	samples.		
Gene	mutation	status	is	nowadays	mainly	determined	using	molecular	technologies	after	DNA	
extraction	such	as	PCR	(=	real-time	polymerase	chain	reaction),	SNaPshot,	Sanger	sequencing,	
together	with	other	validated	methods	in	the	field	of	molecular	pathology.	Concerning	BRAF	
mutations,	 BRAF	 Exon	 15	 PCR	 amplification	 and	 sequencing	 of	 genomic	 DNA	 is	 the	 gold	
standard	 for	 BRAF	 analysis	 in	 melanoma	 samples.	 However,	 molecular	 genetic	 tests	 are	
expensive	and	time	consuming,	can	be	only	performed	in	selected	pathology	departments	and	
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are	 not	worldwide	 available.	 Financial	 issues	 play	 an	 important	 role,	 since	 equipment	 and	
reagents	for	molecular	analysis	are	quite	expensive.	Since	molecular	pathology	tests	require	
tumour	 samples	 which	 are	 fixed	 in	 formalin	 and	 embedded	 in	 paraffin,	 the	 meanwhile	
worldwide	 available	 immunohistochemistry	 technique	 (IHC)	 represents	 an	 appealing	
alternative	method.	
Since	different	melanoma	subtypes	can	be	distinguished	based	on	genetic	mutations	such	as	
BRAFV600E,	corresponding	morphological	patterns	might	also	be	hypothesized.	Reflectance	
confocal	 microscopy	 (RCM)	 and	 dermoscopy	 were	 used	 as	 in-vivo	 techniques,	 while	
immunohistochemistry	(IHC),	cheaper	than	PCR	and	available	in	most	countries,	was	selected	
as	ex-vivo	method.	
Dermoscopy	
	
Dermoscopy	refers	to	the	examination	of	skin	lesions	using	skin	surface	or	epiluminescence	
microscopes.(15,	 16)	 Dermoscopes	 are	 handheld	 devices	 using	 visible	 non-polarized	 and	
polarized	 light	 to	 visualize	 skin	 structures	 up	 to	 40x	magnification.	 They	 are	 portable	 and	
relatively	cheap.	Skin	examination	through	dermoscopy	requires	a	 liquid	(water,	 immersion	
oil	or	alcohol-based	disinfection	spray)	to	reduce	the	reflectivity	of	the	skin	and	enhance	the	
transparency	of	the	stratum	corneum.	Digital	dermoscopes	with	a	magnification	of	up	to	400x	
are	also	available.	A	non-invasive	examination	of	so-called	dermoscopic	patterns	consents	an	
analysis	 of	 epidermis,	 dermo-epidermal	 junction	 and	 papillary	 dermis,	 based	 on	 the	
distribution	 of	melanin,	 keratin	 and	 vascular	 structures.(17)	 Dermoscopy	 is	 now	 the	 gold-
standard	for	the	first	level	diagnostic	of	skin	cancer.	Numerous	studies	in	the	last	thirty	years	
reported	 an	 increase	 of	 sensitivity	 from	 60%	 up	 to	 99%	 for	 diagnosing	melanoma(18-20).	
Cochrane	meta-analyses	have	recently	confirmed	a	superiority	of	dermoscopy	in	comparison	
to	 simple	 clinical	 examination	while	 diagnosing	melanoma	 and	 non-melanoma	 skin	 cancer.	
(21)	Numerous	formal	algorithms	for	optimizing	melanoma	diagnosis	with	dermoscopy	have	
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been	published	so	far,	although	they	appear	to	be	more	of	use	for	training	purposes	and	less	
for	expert	observers(19-22).	Main	dermoscopic	patterns	associated	to	malignant	melanocytic	
lesions	are(17,	18,	22-24):	
− Blue-whitish	veil	
− Multiple	irregular	dots	
− Pseudopods	
− Radial	streaming	
− Scar-like	depigmentation	
− Peripheral	black	dots/globules	
− Multiple	colours	
− Broadened	pigment	network	
− Focal	sharply	cut-off	border	
− Inverse	network	
− Irregular	vessels	
	
Reflectance	confocal	microscopy	
	
Reflectance	 confocal	microscopy	 is	 a	 second-level	 diagnostic	 tool	 to	 dermoscopy;	 it	 allows	
visualization	 of	 skin	 structures	 to	 a	 near	 histologic	 resolution,	 avoiding	 unnecessary	
excisions.(25)	The	commercially	available	RCMs	(Vivascope1500	and	3000-handheld	device,	
MAVIG	GmbH,	Munich,	Germany)	use	a	diode	laser	with	a	near-infrared	wavelength	of	830	nm	
at	 a	 low	 (<25	mW)	 laser	 power	 that	 does	 not	 harm	 human	 tissues.	 The	 imaging	 depth	 is	
limited	 to	 the	 papillary	 dermis	 (around	 200–300	 µm).(26)	 The	 machine	 generates	 basic	
images	with	a	500	µm	x	500	field	of	view;	those	can	be	arranged	either	in	a	2D	mosaic	grid	of	
contiguous	horizontal	images	(VivaBlock)	or	in	a	vertical	sequence	that	is	captured	in	depth	
(VivaStack).	With	the	handheld	device,	it	is	possible	to	examine	difficult	to	access	skin	regions,	
directly	 exploring	 large	 skin	 areas,	with	 a	 little	wider	 field	of	 view	 (800	µm	x	800	µm).	An	
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Image	Control	 System	automatically	 adjusts	 laser	 power	 for	 best	 image	quality,	 so	 that	 the	
entire	field	can	be	quickly	and	directly	explored.	A	dermoscopic	camera	is	also	integrated	to	
permit	a	live	navigation	of	the	scanned	areas.	
RCM	 has	 proven	 its	 utility	 in	 diagnosing	melanoma	 compared	 to	 dermoscopy	 especially	 in	
difficult	 lesions.(27)	 It	 has	 a	 reported	 sensitivity	 of	 93,5%	 and	 specificity	 of	 78,8%	 for	
diagnosing	pigmented	melanomas;	a	sensitivity	of	67%	and	specificity	of	89%	were	described	
for	amelanotic	melanomas.(28-30)	
Main	RCM	morphologic	criteria	associated	to	malignant	melanoma	are:	(31-35)	
In	the	superficial	epidermal	layers	(stratum	granulosum-spinosum):	
− Disarranged	epidermal	pattern	with	atypical	honeycombed	pattern	
− Pagetoid	spread	of	cells	(round	and	dendritic)		
At	the	dermo-epidermal	junction:	
− Non-edged	papillae		
− Dense	and	sparse	nests		
− Junctional	thickening		
− Pagetoid	cells	
− Sheet-like	distribution	of	atypical	melanocytic	cells		
In	the	superficial	dermis:	
− Dense	and	sparse	nests		
− Cerebriform	nests		
	
Immunohistochemistry	
	
Immunohistochemistry	(IHC)	is		an	immunofluorescence	technique	for	detecting	cellular	
antigens	in	tissue	sections,	worldwide	used	in	the	daily	routine	for	infectious	and	neoplastic	
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diseases.(36)	IHC	is	based	on	the	identification	of	specific	tissue	antigens	(Ag)	through	
specific	antibodies	(Ab),	mainly	Immunglobulines	G.	These	are	marked	by	a	colored	
histochemical	reaction	and	become	visible	by	light	microscopy	or	fluorochromes	with	
ultraviolet	light.	Nowadays,	extremely	sensitive	methods	are	available	even	for	multiple	tissue	
sections	at	the	same	time	(microarray	technology).(37)	
Melanomas	tend	to	mimic	the	histologic	features	of	different	tumours,	such	as	
neuroendocrine	tumours,	lymphomas,	sarcomas,	poorly	differentiated	carcinomas	and	germ	
cell	tumours.	For	this	reason,	IHC	is	of	outmost	importance	in	their	differentiation	in	
conventionally	stained	sections(38).	Established	IHC	markers	for	melanoma	are:	
− S100	
− HMB45	
− MART-1/Melan-A	
− Tyrosinase	
− MITF	
− NKI/C3	
− Vimentin	
IHC	together	with	conventional	histology	of	Hematoxylin	&	Eosin	(H&E)	stained	tissue	
samples	is	the	gold	standard	for	the	diagnosis	of	melanoma.(39)		
Also	genetic	mutated	proteins	can	be	targeted	by	specific	antibodies.	IHC	in	this	case	has	the	
advantage	of	allowing	the	direct	visualization	of	protein	distribution	inside	the	specimen	by	
light	microscopy	to	analyse	tissue	heterogeneity.	Moreover,	it	is	able	to	visualize	even	single	
mutated	cells.	Various	BRAF-V600E	specific	antibodies	are	commercially	available	and	have	
been	validated	with	a	reported	sensitivity	of	94%	and	a	specificity	of	95%.(40-45).		
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Aim	of	this	study	was	to	identify	morphological	correlates	able	to	differentiate	BRAF	mutated	
melanomas	compared	 to	 their	wild	 type	counterpart,	based	on	alternative	methods	such	as	
RCM,	dermoscopy	and	IHC.	
Objectives	
This	cumulative	work	is	focused	on	the	attempt	to	describe	morphological	features	able	to	
distinguish	BRAFV600E	mutated	melanomas	from	wild	type	melanomas.	This	might	help	to	
find	interesting	hints	for	screening	melanoma	mutational	status	prior	to	excision	through	
non-invasive	methods	such	as	dermoscopy	and	RCM	or	right	after	surgery	in	the	
histopathology	laboratory,	while	proceeding	to	conventional	evaluation.	Both	works	were	
pilot	studies	on	small	samples.	
In	 the	 paper	 "Confocal	 microscopy	 characterization	 of	 BRAFV600E	 mutated	
melanomas"(46)	we	analysed	eight	BRAFV600E	mutated	melanomas	(six	primary	and	two	
metastases),	 paired	with	 age-,	 sex-	 and	 tumour	 thickness-	matched	wild-type	 controls,	 that	
had	been	 imaged	with	dermoscopy	and	 in-vivo	 confocal	microscopy	prior	 to	 their	 excision.	
Two	 physicians	 expert	 in	 dermoscopy	 and	 confocal	 microscopy	 evaluated	 six	 typical	
dermoscopy	 features	 (“irregularly	 distributed	 globules	 and	 dots”,	 “blue–gray	 blotches”,	
“irregular	 vessels”,	 “white	 regression”,	 “peppering”)	 and	 six	 common	 RCM	 parameters	
(“pleomorphic	pagetoid	cells”,	 “architectural	disarrangement”,	“dischoesed	 junctional	nests”,	
“bright	 particles”,	 “collagen	 bundles”,	 “plump	 bright	 cells”).	 Such	 melanoma-associated	
dermoscopic	 and	 confocal	 patterns	 belong	 to	 the	 list	 of	 widely	 recognized	 morphologic	
criteria	in	the	clinical	practice	and	international	textbooks,	scientific	literature	and	consensus	
guidelines.(17,	18,	23,	24,	34,	35,	47)	A	statistical	analysis	to	calculate	the	frequency	for	each	
parameter	 in	 BRAFV600E	 mutated	 melanomas	 was	 performed.	 Aim	 of	 this	 study	 was	 to	
observe	 whether	 specific	 morphological	 patterns	 were	 more	 common	 in	 BRAF	 mutated	
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melanomas	 compared	 to	 their	wild-type	 counterpart,	 in	order	 to	pre-screen	 the	mutational	
status	of	patients	before	the	excision	and	ideally	plan	a	targeted	therapy	if	necessary.(46,	48)		
Analogously,	in	the	article	"BRAFp.V600E,	p.V600K,	and	p.V600R	Mutations	in	Malignant	
Melanoma:	 Do	 They	 Also	 Differ	 in	 Immunohistochemical	 Assessment	 and	 Clinical	
Features?"(48)	 we	 selected	 eighteen	melanomas	 with	 known	 BRAF	mutational	 status	 (six	
V600E,	seven	V600K,	one	V600R	and	four	wild	type)	determined	through	Sanger	sequencing	
for	which	full	tissue	samples	of	the	primary	tumour	were	available.	We	then	performed	IHC	
with	 BRAFV600E	 (clone:	 VE1,	 1:100)	 (Spring	 Bioscience,	 Pleasanton,	 CA)	 antibodies.	 The	
results	were	separately	evaluated	by	two	pathologists,	blinded	to	the	mutational	status.	The	
aim	was	to	determine	whether	IHC	was	able	to	recognize	BRAFV600	mutated	melanomas,	in	
order	 to	 provide	 a	 cost-effective	 and	 quicker	 method	 to	 screen	 melanomas	 for	 their	
mutational	status	without	using	expensive	and	time-consuming	molecular	pathology.	
State	of	art	
The	 articles	 discussed	 in	 this	 cumulative	 dissertation	 were	 published	 in	 2015(46)	 	 and	
2016(48),	 respectively.	 Pozzobon	 and	 colleagues	 (49)	 had	 retrospectively	 analyzed	
dermoscopic	 findings	 in	 a	 cohort	 of	 72	BRAF	mutated	melanomas	 in	 2014.	 They	described	
peppering,	already	known	as	expression	of	regression	and	melanophages	in	the	dermis,	as	an	
expression	 of	 immune	 reaction	 in	 BRAF	 mutated	 melanomas.	 In	 2017,	 Bombonato	 and	
colleagues	 associated	 irregular	 peripheral	 streaks	 and	 ulceration	 to	 BRAF	 mutated	
melanomas	and	dotted	vessels	to	wild	type	melanomas.	They	could	not	find	any	statistically	
significant	association	between	RCM	features	and	mutational	status.	(50)	In	2018,	a	Spanish	
study	came	to	different	results,	identifying	blue-whitish	veil	as	the	only	relevant	parameter	in	
the	differentiation	of	BRAFV600E	mutated	and	wild	type	melanomas.(51)	Our	study	was	the	
first	to	look	for	a	RCM	correlation	of	BRAF	mutated	melanomas.	
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Concerning	IHC,	the	need	for	cheaper	and	quicker	alternative	methods	to	molecular	pathology	
was,	since	the	advent	of	effective	molecular	targeted	therapies,	clear.	The	most	recent	studies	
on	 the	 topic	 report	 a	 good	 overall	 concordance	 of	 IHC	 (89%	 to	 95%)	with	 PCR	 associated	
methods,	however	limited	to	BRAFV600E.(40,	41,	52).	
 
Results	
	
Most	 common	 dermoscopic	 features	 in	 BRAFV600E	 mutated	 melanomas	 were	 irregularly	
distributed	 dots	 and	 globules	 and	 blue-gray	 blotches	 (62%),	 followed	 by	 irregular	 vessels,	
white	 regression,	 and	 peppering	 (50%).	 Most	 common	 RCM	 patterns	 were:	 “pleomorphic	
pagetoid	 cells”,	 “disarrangement	 at	 the	 dermo-epidermal	 junction”	 (DEJ),	 “decohesed	
junctional	nests”,	and	“bright	particles	at	the	DEJ”	(75%).	
Peppering	in	dermoscopy	and	plump	bright	cells	in	RCM	were	more	common	in	BRAFV600E	
melanomas	 than	 in	 wild-type	 ones	 (63%	 and	 37%,	 respectively).	 Additionally,	 we	 could	
associate	 the	 RCM	 detected	 inflammation	 at	 the	 DEJ	 (collagen	 bundles,	 plump	 bright	 cells,	
bright	particles)	to	the	dermoscopic	feature	“peppering”.	
In	IHC,	V600E	specific	antibody	stained	all	melanomas	harbouring	V600E	and,	interestingly,	
the	only	melanoma	harbouring	V600R	mutation,	but	was	not	able	to	recognize	BRAF	V600K	
mutated	melanomas.	All	V600E	and	wild	type	cases	were	correctly	identified	by	the	2	
pathologists	and	the	overall	concordance	rate	between	protein	expression	and	BRAFV600E	
mutations	was	100%	(6/6).	The	single	BRAFV600R	mutated	melanoma	had	a	strong	
cytoplasmic	staining.	The	7	BRAF	p.V600K-mutated	melanomas	were	reported	as	negatively	
stained	by	both	observers.		
Also	prognostic	data	analysis	was	in	line	with	similar	studies,	recording	the	worst	prognosis	
for	patients	with	V600K	mutated	melanomas.	
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Conclusions	
	
The	BRAF	mutational	profiling	of	melanomas	is	nowadays	necessary	to	classify	patients	based	
on	potential	adjuvant	and	therapeutic	strategies.	Today,	the	gold	standard	for	the	mutational	
analysis	are	molecular	technologies	such	as	high-resolution	melting	(HRM)	analysis,	together	
with	 sequencing,	 Sanger	 bidirectional	 sequencing,	 pyrosequencing,	 and	 next-generation	
sequencing	 (NGS)	 with	 special	 gene-panels.	 Above-mentioned	 methods	 are	 however	 quite	
pricey	and	timewasting,	require	trained	technicians,	conspicuous	tissue	samples,	and	are	not	
worldwide	available.		
The	 search	 for	 morphological	 predictors	 of	 mutational	 status	 remains	 an	 actual	 topic,	
especially	concerning	cost-effective	screening	methods.	
Dermoscopy	 and	 confocal	 microscopy	 are	 related	 to	 each	 other	 and	 might	 provide	 useful	
information	 in	 the	 non-invasive	 initial	 categorization	 of	 melanoma	 patients	 potentially	
harbouring	a	BRAFV600E	mutation.		
Histopathological	examination	represents	the	gold	standard	in	the	diagnosis	of	melanocytic	
tumours.	It	is	thus	proven	that	RCM	is	useful	in	the	characterization	of	cellular	and	structural	
alterations	in	nevi	and	melanomas,	with	specific	histological	correlations.	A	preliminary	study	
could	also	find	peculiar	RCM	features	in	subjects	with	multiple	melanomas	harbouring	
CDKN2A	and	MC1R	genetic	variants.	
RCM	is	a	valuable	tool	especially	in	those	lesions	where	dermoscopy	alone	is	not	able	to	make	
a	diagnosis	of	melanoma	with	enough	confidence.	The	potential	ability	of	RCM	to	evaluate	
main	morphologic	patterns	in	melanomas	is	evident	also	in	the	cases	where	dermoscopy	
cannot	identify	them.	For	example,	regression	features	(corresponding	to	“bright	and	
thickened	hyperrefractive	collagen	fibers	and	plump	bright	cells)	could	be	seen	also	in	those	
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melanomas	where	peppering	(a	dermoscopic	correlate	for	inflammation	and	fibrosis)	was	not	
found.	Those	parameters	were,	in	fact,	seen	in	the	histological	examination.	
 
At	 the	 same	 time,	 ICH	might	 be	 efficiently	 used	 for	 the	 preliminary	 search	 of	 BRAFV600E	
mutations	 in	 subjects	with	high	 risk	or	metastatic	melanomas	potentially	benefiting	 from	a	
systemic	 therapy	with	 BRAF	 inhibitors.	 Compared	 to	molecular	 pathologic	methods,	 IHC	 is	
easier	to	perform	by	trained	technicians	and	can	be	performed	in	the	same	time	window	for	
different	antibodies	such	as	S100.		It	 allows the direct visualization of mutational distribution in 
the tumour sample and therefore tissue heterogeneity. It is cheaper and can be performed in most 
pathology departments worldwide. Hence, it represents a cost-effective and rapid screening method 
for BRAFV600E mutations in melanomas. However, IHC should	 be	 followed	 by	 molecular	
techniques	 in	 V600E-negative	 melanomas,	 since	 the	 commercially	 available	 antibodies	 are	
mainly	not	able	to	identify	V600K	and	other	rare	nonV600E	BRAF	mutations.		
Both	 studies	 are	 limited	 by	 the	 small	 sample	 size,	 so	 that	 they	 should	 be	 considered	
preliminary	and	further	developments	in	larger,	prospective	cohorts	are	needed.		
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Zusammenfassung	(Deutsch)	
	
Hintergrund	
Seit	dem	Aufkommen	molekularer	zielgerichteter	Therapien	ist	die	Mutationsprofilierung	von	
malignen	 Melanomen	 von	 größter	 Bedeutung	 geworden.	 Melanome	 können	 anhand	 des	
Vorhandenseins	von	BRAF-Mutationen	unterschieden	werden.	Schätzungsweise	40-60%	der	
Melanome	 weisen	 eine	 BRAF-Mutation	 auf,	 die	 meisten	 davon	 V600E.	 Aktuelle	 Richtlinien	
empfehlen,	 jedes	 fortgeschrittene	 Melanom	 auf	 BRAF-Mutationen	 zu	 testen,	 da	 BRAF-
Inhibitoren	 sowohl	 im	 adjuvanten	 als	 auch	 im	 therapeutischen	 Setting	 verfügbar	 sind.	
Molekularpathologische	 Techniken	 sind	 der	 Goldstandard	 für	 den	 Nachweis	 von	 BRAF-
Mutationen,	 insbesondere	 die	 Ampflizierung	 und	 Sequenzierung	 von	 BRAF	 Exon	 15	 aus	
genomischer	 DNA	 mittels	 PCR.	 Solche	 Tests	 sind	 jedoch	 teuer	 und	 zeitaufwändig.	 Da	
verschiedene	 Melanom-Subtypen	 anhand	 genetischer	 Mutationen	 wie	 BRAFV600E	
unterschieden	werden	können,	können	entsprechende	morphologische	Muster	angenommen	
werden.	Ziel	dieser	Studie	war	es,	BRAF-mutierte	Melanome	im	Vergleich	zu	ihrem	Wildtyp-
Korrelat	auf	der	Grundlage	alternativer	Methoden	wie	konfokaler	in-vivo-Mikroskopie	(RCM),	
Dermatoskopie	und	Immunhistochemie	(IHC)	weiter	zu	charakterisieren.	
Methoden	
Acht	 mutierte	 BRAFV600E-Melanome	 (sechs	 primäre	 und	 zwei	 Metastasen),	 gepaart	 mit	
alters-,	 geschlechts-	 und	 tumourdickenangepassten	 Wildtyp-Kontrollen,	 wurden	 mit	
Dermoskopie	und	konfokaler	in-vivo-Mikroskopie	analysiert.	
Auf	 der	 anderen	 Seite	 wurden	 18	 Melanome	 mit	 bekanntem	 BRAF-Mutationsstatus	
(BRAFV600E,	 V600K,	 V600R	 und	 Wildtyp)	 zusätzlich	 durch	 Immunhistochemie	 mit	 Anti-
BRAF-Antikörpern	bewertet.	
Ergebnisse	
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Die	 häufigsten	 dermatoskopischen	Merkmale	 bei	mutierten	BRAFV600E-Melanomen	waren	
unregelmäßig	 verteilte	 Punkte	 und	 Schollen	 sowie	 grau-blaue	 homogene	 Areale	 (62%),	
gefolgt	 von	 unregelmäßigen	 Gefäßen,	 weißer	 Regression	 und	 Peppering	 (50%).	 Die	
häufigsten	 RCM-Muster	 waren	 pleomorphe	 pagetoide	 Zellen,	 Störungen	 der	 dermo-
epidermalen	 Junktion	 (DEJ),	 atypische	 junktionale	Melanozytennester	 und	 helle	 Partikel	 an	
der	DEJ	(75%).	
	Peppering	 in	 der	 Dermatoskopie	 und	 plumpe	 helle	 Zellen	 in	 RCM	 wurden	 häufiger	 in	
mutierten	 primären	BRAFV600E-Melanomen	 als	 in	Wildtyp-Melanomen	 gefunden	 (63%	vs.	
37%).	
In	 der	 IHC	 färbte	 der	 V600E-spezifische	 Antikörper	 alle	 Melanome,	 die	 eine	 V600E-	 und	
V600R-Mutation	 enthielten,	 konnte	 jedoch	 keine	 BRAF	 V600K-mutierten	 Melanome	
erkennen.	
Schlussfolgerungen	
Dermatoskopie	 und	 konfokale	 Mikroskopie	 zeigen	 eine	 gute	 Korrelation	 zueinander	 und	
könnten	 nützliche	 Informationen	 für	 das	 nicht-invasive,	 preliminäre	 Screening	 und	 die	
Charakterisierung	von	BRAFV600E-mutierten	Melanomen	liefern.	
Gleichzeitig	könnte	die	Immunhistochemie	als	erster	Schritt	zum	Nachweis	der	BRAFV600E-
Mutation	bei	der	Auswahl	von	Patienten	mit	fortgeschrittenen	Melanomen	als	Kandidaten	für	
eine	systemische	Therapie	mit	BRAF-Inhibitoren	wirksam	eingesetzt	werden.	 IHC	sollte	von	
molekularen	Techniken	bei	p.V600E-negativen	Melanomen	gefolgt	werden,	um	p.V600K	und	
andere	seltene	Nicht-V600E-BRAF-Mutationen	zu	entdecken.	
	
Schlüsselworte:	 Malignes	 Melanom,	 BRAF	 Mutation,	 Immunhistochemie,	 konfokale	
Laserscanmikroskopie,	nicht-invasive	Diagnostik.	
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Abstract	(English)	
Background	
Since	the	advent	of	molecular	targeted	therapies,	mutational	profiling	of	malignant	melanoma	
has	become	of	outmost	importance.	Melanomas	can	be	distinguished	based	on	the	presence	of	
BRAF	mutations.	Estimated	40-60%	of	melanomas	harbour	a	BRAF	mutation,	most	of	 them	
V600E.	Current	guidelines	recommend	testing	every	advanced	melanoma	for	BRAF	mutation,	
since	BRAF	inhibitors	are	available	for	both	adjuvant	and	therapeutic	setting.	BRAF	Exon	15	
PCR	 amplification	 and	 sequencing	 of	 genomic	 DNA	 now	 represents	 the	 gold	 standard	 for	
BRAF	analysis	in	melanoma	samples.	Molecular	genetic	tests	are	however	expensive	and	time	
consuming.	 Since	 different	 melanoma	 subtypes	 can	 be	 distinguished	 based	 on	 genetic	
mutations	 such	 as	 BRAFV600E,	 corresponding	 morphological	 patterns	 might	 be	
hypothesized.	 Aim	 of	 this	 study	 was	 to	 further	 characterize	 BRAF	 mutated	 melanomas	
compared	 to	 their	 wild	 type	 counterpart	 based	 on	 alternative	 methods	 such	 as	 in-vivo	
confocal	microscopy	(RCM),	dermoscopy	and	immunohistochemistry	(IHC).	
Methods	
Eight	BRAFV600E	mutated	melanomas	 (six	primary	and	 two	metastases),	 paired	with	age-,	
sex-	and	tumour	thickness-	matched	wild-type	controls	were	analysed	with	dermoscopy	and	
in-vivo	confocal	microscopy.	
On	 the	 other	 side,	 eighteen	melanomas	 with	 known	 BRAF	mutational	 status	 (BRAFV600E,	
V600K,	 V600R	 and	 wild-type)	 were	 additionally	 evaluated	 through	 immunohistochemistry	
with	anti-BRAF	antibodies.	
Results	
Most	 common	 dermoscopic	 features	 in	 BRAFV600E	 mutated	 melanomas	 were	 irregularly	
distributed	 dots	 and	 globules	 and	 gray-blue	 blotches	 (62%),	 followed	 by	 irregular	 vessels,	
white	 regression,	 and	 peppering	 (50%).	 Most	 common	 RCM	 patterns	 were	 pleomorphic	
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pagetoid	 cells,	 disarrangement	 at	 the	 dermoepidermal	 junction	 (DEJ),	 decohesed	 junctional	
nests,	and	bright	particles	at	the	dermal–epidermal	junction	(75%).	
Peppering	 in	 dermoscopy	 and	 plump	 bright	 cells	 in	 RCM	 were	 more	 frequently	 found	 in	
BRAFV600E	 mutated	 primary	 melanomas	 compared	 to	 wild-type	 ones	 (63%	 and	 37%,	
respectively).		
In	 IHC,	 V600E-specific	 antibody	 stained	 all	 melanomas	 harbouring	 V600E	 and	 V600R	
mutation,	but	was	not	able	to	recognize	BRAF	V600K-mutated	melanomas.		
Conclusions	
Dermoscopy	 and	 confocal	 microscopy	 are	 related	 to	 each	 other	 and	 might	 provide	 useful	
information	 in	 the	 non-invasive	 initial	 categorization	 of	 melanoma	 patients	 potentially	
harbouring	a	BRAFV600E	mutation.		
At	the	same	time,	IHC	might	be	a	useful	tool	for	the	initial	diagnosis	of	a	BRAFV600E	mutation	
in	 subjects	 with	 high	 risk	 or	 metastatic	 melanomas	 potentially	 benefiting	 from	 a	 systemic	
therapy	with	BRAF	inhibitors.	After	the	IHC	screening,	molecular	techniques	shall	be	used	in	
V600E	wild	type	melanomas,	in	the	search	for	less	frequent	non-V600E	BRAF	mutations.		
Keywords:	malignant	melanoma,	 BRAF	mutation,	 immunohistochemistry,	 reflectance	 confocal	
microscopy,	non-invasive	diagnostics.	
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Immunohistochemical Assessment and Clinical Features?
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Introduction: Although the detection of BRAF p.V600E muta-
tion by immunohistochemistry was clearly described in mela-
noma, discordant evidences were reported for the detection of
p.V600K and p.V600R mutations. The aim of the study was to
evaluate the efficacy of BRAFp.V600E, p.V600K, and p.V600R
detection by immunohistochemistry in melanoma.
Materials and Methods: Immunohistochemistry with VE1 anti-
body was performed on 18 tissue samples of metastatic mela-
nomas with known BRAF mutational status.
Results: The concordance rate of immunohistochemistry was
100% for p.V600E mutation. In contrast, the 7 p.V600K-mu-
tated melanomas were scored as negative. p.V600K-mutated
melanomas were significantly associated with older age, male
sex, and worst clinical outcome.
Conclusions: Immunohistochemistry could efficaciously be
adopted as a first step for the detection of BRAFp.V600E mu-
tation in the initial selection of patients with advanced mela-
nomas as candidates for BRAF inhibitors. It should be followed
by molecular techniques in p.V600E-negative melanomas, for
the specific search of p.V600K and other non-p.V600E BRAF
mutations.
Key Words: BRAFp.V600K mutation, BRAFp.V600E im-
munohistochemical assessment, malignant melanoma,
BRAFp.V600R mutation, BRAF inhibitors
(Appl Immunohistochem Mol Morphol 2016;24:30–34)
About 40% to 60% of malignant melanomas are BRAFmutated.1,2 The most common mutations are
BRAFp.V600E (80%) and BRAFp.V600K (5-30%).3
These mutations result (mainly p.V600E) in an enhanced
BRAF kinase activity and an increased phosphorylation
of downstream targets, particularly MEK. Nowadays, the
evaluation of somatic BRAF mutations is required for
molecular-targeted treatments of metastatic melanoma.
In fact, BRAF inhibitors targeting common p.V600E
mutations have become increasingly popular because of
their high objective response rate and few side effects.
BRAF inhibitors have a clinical activity also in melanoma
patients harboring a non-p.V600E BRAF mutation, par-
ticularly p.V600K and p.V600R.4–6 BRAFp.V600M-D
are quite rare and they were not included in the trials for
BRAF-selective inhibitors.5
The ability to recognize BRAFp.V600E mutation
changes according to the methods used for mutation
testing. At present time, the cobas 4800 BRAFp.V600
Mutation Test, approved by FDA and specifically created
to detect BRAFp.V600E mutation, is able to detect 70%
of BRAFp.V600K mutations.7
Although the immunohistochemical assessment of
p.V600E mutation was clearly reported in melanoma and
other tumors,8,9 discordant evidences were reported for
p.V600K BRAF mutations.2,10 Different authors reported
that none of the non-p.V600E cases, including p.V600K,
stained positive with the antibody8,9; in contrast,
Routhier et al10 and Heinzerling et al11 described 2
p.V600K melanomas with positive VE1 staining.
The aim of this paper was to assess the efficacy of
BRAFp.V600E and p.V600K detection by immuno-
histochemistry in melanoma and the distinctive clinical
features of the most common BRAF mutations.
PATIENTS AND METHODS
We selected 35 patients with BRAF-positive ad-
vanced melanoma, diagnosed at the University of Mod-
ena and Reggio Emilia from January 2010. Among these,
18 patients with known BRAF mutational status (12
males, 6 females) were included (Table 1). The 22 re-
maining tissues could not be IHC tested because of
nonavailability of enough sample or missing informed
consent. We decided to analyze the patients’ data and
include them in the study because of their epidemiological
importance.
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Tumor samples were collected according to the
principles of the Declaration of Helsinki after obtaining
informed consent from each patient. The study was ap-
proved by the institutional review board.
IMMUNOHISTOCHEMISTRY
Eighteen melanomas referred for genotyping assay
at our Molecular Diagnostic Laboratory were retrieved
from the pathology database, all with known BRAF
mutational status: p.V600E (n=6), p.V600K (n=7),
p.V600R (n=1), and WT (n=4).
Immunohistochemistry with anti-BRAF antibody
was performed on 5-mm-thick whole tissue sections of
formalin-fixed, paraffin-embedded tissue in a automated
immunostainer (Benchmark XT, Ventana) and primary
antibodies against BRAFp.V600E (clone: VE1, 1:100)
(Spring Bioscience, Pleasanton, CA). All slides were
double-blind reviewed by 2 independent observers
(A.M.C. and M.M.). The VE1 antibody staining was
scored as negative when there was no staining or only
isolated nuclear staining. Positive staining was considered
by diffuse and moderate (2+) to strong (3+) cytoplasmic
staining. Staining results were interpreted as negative
when there was no staining (0+), or also slight/faint/
barely perceptible staining or staining of only single cells
(1+).
BRAF MUTATION ANALYSIS
Two pathologists reviewed all H&E-stained slides of
primary melanomas. The tumor area of interest was de-
tected and marked on each specimen. DNA was extracted
using the DNeasy Blood & Tissue Kit (Qiagen, Basel,
Switzerland) and tested for BRAF mutations in 2 different
laboratories.
Sanger sequencing analyses was performed on all
samples to determine BRAF mutational status. The PCR
product were checked for the right fragment length, pu-
rified and sequenced as previously described.4 Data were
manually edited with the sequencing analysis software
(Applied Biosystems, Darmstadt, Germany).
RESULTS
Average ages were 59 years for patients with p.V600E
and 66 years for patients with p.V600K (Table 1).
BRAFp.V600K-mutated patients had a worse prognosis
compared with their V600E counterparts (Table 2).
The correlation between immunohistochemistry for
VE1 antibody and BRAF mutational status is shown
in Table 1. V600E-specific antibody stained 6 p.V600E-
mutated melanomas, but no BRAF wild-type or
p.V600K-mutated melanomas. All p.V600E and wild-
type cases were correctly identified by the 2 pathologists
and the overall concordance rate between protein ex-
pression and BRAFp.V600E mutations was 100% (6/6).
The single BRAFp.V600R-mutated melanoma had a
strong cytoplasmic staining. The 7 BRAF p.V600K-mu-
tated melanomas were reported as negatively stained with
VE1 by both observers (Table 1).
In all cases, the interobserver agreement was almost
total. Cross reactivity was not observed (Fig. 1).
DISCUSSION
Our study shows that, in contrast to BRAFp.V600E
mutation, BRAFp.V600K is not detected by im-
munohistochemistry with VE1 antibody. Our analysis
confirms the high sensitivity and specificity of VE1 anti-
body in detecting p.V600E mutation, as seen in recently
published studies.8–10 Although isolated instances of
VE1 reactivity in p.V600K-mutant melanoma have been
reported, our findings clarify the value of this antibody as
a screening tool for V600E mutations.10,11
Even though our results are based on a small sample
size and further studies are still needed to set appropriate
diagnostic standards, we can still highlight some key
concepts.
Although BRAF inhibitors are efficacious on tu-
mors with p.V600E and p.V600K mutations, the 2 tumor
types shall be considered as distinct entities with slightly
different age of onset and clinical behavior.2,3
Regarding the response to treatment, the clinical
trials with vemurafenib/dabrafenib including patients
with p.V600K mutations reported worse outcomes and a
strong trend for shorter overall survival (OS) among
p.V600K melanoma patients compared with those with
BRAFp.V600E mutation.2
Recently published studies demonstrated that pa-
tients with BRAFp.V600K mutation are characterized by
an older age of cancer onset, an increased risk for brain
and lung metastases, and a shorter time from diagnosis to
TABLE 1. Correlation of BRAF Mutation Status With
Monoclonal VE1 Immunostaining Evidences
ID Sex Age (y)
BRAF Mutation
Types
VE1 Staining
Pathologist 1
VE1 Staining
Pathologist 2
1 M 69 V600E 3+ 3+
2 F 51 V600E 3+ 3+
3 M 51 V600E 3+ 3+
4 M 50 V600E 3+ 3+
5 F 67 V600E 3+ 3+
6 M 66 V600E 3+ 3+
7 M 75 V600K 0 0
8 M 48 V600K 0 0
9 M 62 V600K 0 0
10 M 74 V600K 0 0
11 M 69 V600K 0 0
12 F 51 V600K 0 0
13 M 82 V600K 0 0
14 M 61 V600R 2+ 2+
15 F 68 WT 0 0
16 M 68 WT 0 0
17 F 70 WT 0 0
18 F 41 WT 0 0
BRAF mutations were detected as following: 25 V600E (c. 1799 T>A; codon
GTG>GAG); 2 BRAF V600 “E2” (c.1799_1800TG.AA:p. Val600Glu); 7 V600K
(c.1798_1799GT.AA:p.Val600Lys); 1 V600R (c.1798_1799GT.AG:p.Val600Arg).
F indicates female; M, male.
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metastasis and death. Reports of melanoma patients with
BRAFp.V600E and p.V600K mutations recognized sig-
nificant differences in sex, age, primary melanoma loca-
tion, interval from the time of initial melanoma diagnosis
to diagnosis of stage IV disease, and OS after the diag-
nosis of the stage IV disease. p.V600K mutation was
significantly associated with older age, male sex, head and
neck primary melanoma site, higher degree of chronic sun
damage, and short OS from the time of diagnosis of stage
IV disease.3
Our case series confirm that p.V600K-mutated
melanomas arise at an older age (59 vs. 66 y old) and is
predominant in males. In this case, it arises in the head
and neck area. Their biological behavior is more ag-
gressive and with tendency to systemic disease, compared
with their p.V600E counterparts.
Our experience confirms, according to recent liter-
ature on the same topic, the efficacy of VE1 in the rec-
ognition of BRAFp.V600R mutation12 (Table 1, Fig. 1);
although just 1 melanoma belonging to our cohort was
p.V600R mutated, the clear staining positivity led us to
the hypothesis that the protein conformational change is
similar enough to the one induced by p.V600E to be
bound by VE1 antibody. However, the risk of mis-
identifying p.V600R as p.V600E by IHC is of limited
clinical relevance. p.V600R mutation is less common than
the others, but it is the third most common mutation
occurring in 5% to 7% of patients with BRAF-mutant
melanoma and there are evidences that the melanoma
patients carrying this mutation can be successfully treated
with oral BRAF inhibitors.6,12
It is known that it is very useful to screen all patients
with advanced melanoma (unresectable stage III and IV)
and high risk of recurrence (stage IIIb and IIIc) for
BRAFp.V600 mutations other than p.V600E, so that a
higher number of patients might benefit from BRAF se-
lective inhibitors. With this regard, BRAFp.V600K mu-
tation, which is present in about 20% of melanomas,
should be investigated with a specific antibody at
immunohistochemistry or through direct sequencing. In
contrast to p.V600E and p.V600R, in fact, VE1 antibody
is not able to recognize p.V600K.
To sum up, p.V600K-mutated melanomas seem to
constitute a specific clinical and pathologic entity, show-
ing different features in comparison with their p.V600E
counterparts. This becomes evident if we consider the
different sensitivity to VE1 antibody at immuno-
histochemistry, which requires the use of distinct anti-
bodies for detecting p.V600K mutation.
Moreover, we realized that the immunohisto-
chemical screening for BRAF mutations, which is less
expensive and less time consuming than molecular se-
quencing, can be efficaciously used in the preliminary
screening of the great majority of BRAFp.V600E-mutated
melanomas. This preliminary analysis could be then fur-
ther enriched through the use of a specific antibody for
p.V600K mutation and, eventually, direct sequencing for
other BRAF mutations in case of negative immuno-
histochemical staining.T
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FIGURE 1. Immunohistochemistry with anti-BRAF p.V600E-specific VE1 antibody. p.V600E-mutated case with strong positive
cytoplasmic staining of melanoma cells (A); p.v600E-mutated case with strong positive cytoplasmic staining of melanoma cells
(B); p.V600R-mutated case with positive cytoplasmic staining of melanoma cells ("20) (C); p.V600R-mutated case with positive
cytoplasmic staining of melanoma cells ("40) (D); p.V600K-mutated case with negative cytoplasmic staining (E); BRAF wild-type
(WT) case with negative cytoplasmic staining (F).
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Confocal microscopy characterization of BRAFV600E
mutated melanomas
Cristel Ruinia,c, Marco Manfredinia, Giovanni Pellacania, Victor D. Mandela,
Aldo Tomasib and Giovanni Pontib
Thanks to modern techniques, molecular signatures for
melanoma are now identifiable and have opened new
horizons in the treatment of metastatic disease with
molecular-targeted therapies. We distinguish different
melanoma subtypes on the basis of genetic mutations such
as BRAFV600E and we can therefore hypothesize the
existence of corresponding morphological patterns that
might be detected in vivo by noninvasive diagnostic tools
such as dermoscopy and confocal microscopy. Eight
BRAFV600E mutated melanomas (six primary and two
metastases) were collected, matched in terms of age, sex,
and thickness wild-type controls, and analyzed. In this
preliminary study, regression, corresponding to fibrosis and
melanophages in the dermis, was the predominant pattern
and was also observed confocally when dermoscopy
showed no peppering. In particular, confocal microscopy
could not only detect regression but also provided a
semiquantitative analysis of its grade through the count of
melanophages. Confocal microscopy can be proposed as a
useful tool in the preliminary screening and characterization
of BRAFV600E mutated melanomas, providing new insights
for patients’ screening and follow-up. Melanoma Res
25:367–371 Copyright © 2015 Wolters Kluwer Health, Inc.
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Introduction
Thanks to the development of increasingly more
sophisticated molecular techniques, it has been possible
to identify molecular signatures for cancers. In the case
of melanoma, the last few years have witnessed the
identification of molecular mutations involved in
the tumorigenesis and the subsequent discovery of
molecular-targeted therapies. Such agents are highly
selected for specific mutations and provide higher
response rates and fewer adverse events than traditional
agents. Around 40–60% of malignant melanomas harbor a
mutation of the BRAF gene [1], mostly V600E; however,
V600K, V600R, and V600D mutations are also known.
Specific BRAF inhibitors such as vemurafenib and
dabrafenib have shown promising results in the
molecular-targeted treatment of BRAF mutated meta-
static melanoma [2,3]. Other newly available tailored
therapies are those with C-KIT and MEK inhibitors [4].
Because different molecular alterations categorize dis-
tinct melanoma subtypes, corresponding to a molecular
signature and distinctive clinical features, it is reasonable
to hypothesize the existence of diverse morphological
patterns [5]. In particular, melanomas with common
genetic mutations might share certain morphological
features detectable with the noninvasive diagnostic tools
used widely in common clinical practice in selected
centers, such as dermoscopy and reflectance confocal
microscopy (RCM). Recently published scientific articles
have reported the analysis of the main dermoscopic dif-
ferences in melanocytic lesions with certain genetic
mutations in some research centers [6–8], but the use of
RCM has not been reported before. In particular,
Pozzobon et al. [7] found that ‘peppering’, the dermo-
scopic pattern expressing regression and the presence of
melanophages in the dermis, is the most common der-
moscopic pattern in BRAF mutated melanomas com-
pared with wild-type melanocytic cancer. We present our
preliminary personal experience in the evaluation of
BRAFV600E mutated melanomas with RCM compared
with wild-type melanomas matched for age, sex, and
thickness.
Methods
Among patients with BRAFp.V600E mutated melanomas
diagnosed in our clinic from January 2010, dermoscopic
and RCM images of eight melanomas (six primary mel-
anomas and two metastases, each from different patients)
stored in our databases were available for evaluation. Six
age-matched, sex-matched, and thickness-matched pri-
mary melanomas and two metastasis controls (each from
different patients) with no known BRAFmutations (wild-
type) were also selected. Dermoscopic and RCM patterns
(Table 1) of both cases and controls lesions were asses-
sed. Dermoscopic images were obtained using a digital
camera Konica Minolta Dimage Z10 3.2 MegaPixels
(Konica Minolta Holdings Inc., Tokyo, Japan) equipped
Short communication 367
0960-8931 Copyright © 2015 Wolters Kluwer Health, Inc. All rights reserved. DOI: 10.1097/CMR.0000000000000147
Copyright r 2015 Wolters Kluwer Health, Inc. All rights reserved.
with a dermatoscope DermLite Photo (3Gen, San Juan
Capistrano, California, USA). Confocal imaging was per-
formed using a near-infrared reflectance-mode confocal
laser scanning microscope (Vivascope1500; Caliber ID,
Rochester, New York, USA). The instrument uses a
diode laser at 830 nm with power less than 16 mW at the
tissue level and a × 30 water-immersion lens. Instruments
and acquisition methods have been described elsewhere
[9]. For the evaluation of dermoscopic and confocal
images, both semiquantitative evaluations and quantita-
tive measurements were obtained. Two expert dermo-
scopists and confocalists evaluated six dermoscopic
patterns and six RCM parameters that were selected to
better characterize invasive melanomas from the wider
group of known dermoscopic and RCM known descrip-
tors (Table 1) [10]. Absolute and relative frequencies
were calculated for each parameter to characterize
BRAFp.V600E mutated melanomas. All lesions were
histologically proven and examined by an expert der-
matopathologist in our department. DNA was extracted
using the DNeasy Blood and Tissue Kit (Qiagen, Basel,
Switzerland) and tested for BRAF mutations in our
laboratory. Sanger sequencing analyses were carried out
on all samples to determine BRAF mutational status.
The PCR products could be directly used for sequencing
analyses, whereas conventionally amplified PCR pro-
ducts were checked for the right fragment length by
agarose gel electrophoresis and purified using MicroSpin
S-300 HR Columns (Amersham Pharmacia Biotech,
Freiburg, Germany) or polyethylene glycol precipitation.
Purified PCR products were sequenced using the
BigDye Terminator v1.1 Cycle Sequencing Kit,
sequences were run on an ABI Prism 3130 automated
sequencer, and data were edited manually using
sequencing analysis software (all from Applied
Biosystems, Darmstadt, Germany).
Results
The group of patients with BRAFp.V600E mutated pri-
mary melanomas included four men and two women,
ranging in age from 36 to 81 years, mean age 53 years.
The two patients with BRAFp.V600E metastases inclu-
ded one man and one woman, ranging in age from 49 to
78 years, mean age 63.5 years. The group of patients with
wild-type BRAF primary melanoma included six patients,
three men and three women, ranging in age from 42 to
85 years, mean age 58 years, whereas the patients with
wild-type melanoma metastases included one man and
one woman, ranging in age from 63 to 72 years, mean age
67.5 years.
The relative frequencies of the dermoscopic and RCM
parameter of BRAFp.V600E mutated primary melanoma
and of wild-type BRAF primary melanoma are shown in
Table 1. In BRAFp.V600E mutated primary melanoma,
the dermoscopic descriptors globules blue–gray blotches
and dots irregularly distributed were each present in 62%Ta
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Fig. 1
(a) (b) (c) (d)
(e) (f) (g) (h)
(i) (j) (k) (l)
(m) (n) (o) (p)
(q) (r) (s) (t)
Clinical (a, e, i, m, q), dermoscopic (b, f, j, n, r), RCM (c, g, k, o, s), and histological (d, h, l, p, t) images of three melanomas with BRAFpV600E (a–l) and
two wild-type melanomas (m–t). Globules, gray blotches, irregular vessels, white regression, irregularly distributed dots are present. RCM patterns
are: pleomorphic pagetoid cells, disarrangement at the dermoepidermal junction, decohesed junctional nests, and bright particles, together with
collagen bundles and plump bright cells. Histological sections confirm the diagnosis of melanoma showing the presence of atypical melanocytes,
mainly aggregated to form dermal nodules, sometimes with regression areas (l). RCM, reflectance confocal microscopy.
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of cases; irregular vessels, white regression, and pepper-
ing were each present in 50% of cases. The RCM analysis
shows that pleomorphic pagetoid cells, disarrangement at
the dermoepidermal junction, decohesed junctional
nests, and bright particles at the dermal–epidermal
junction were each present in 75% of cases. Moreover,
it was possible to correlate the detection of inflammation
at the dermal–epidermal junction (collagen bundles and
plump bright cells or bright particles) with the dermo-
scopic detection of peppering. The grading of the pre-
sence of plump bright cells on a semiquantitative scale
(absent, few, abundant) showed that the abundant pre-
sence of these cells alone was correlated with the pep-
pering phenomena. The detection of plump bright cells
and of the inflammatory RCM parameters at the
dermal–epidermal junction was more frequent than the
detection of the peppering phenomena, being present in
67–75% compared with 50% of cases (Fig. 1). The fre-
quency of dermoscopic descriptors found in wild-type
melanomas marked the difference with BRAF mutated
melanomas: globules were present in 75%, blue–gray
blotches were found in 50%, irregularly distributed dots
were present in 37%, and irregular vessels, white
regression, and peppering were each found in 13% of
cases. The RCM analysis shows that decohesed junc-
tional nests were identified in 75%, disarrangement at the
dermoepidermal junction was present in 62%, pleo-
morphic pagetoid cells were present in 50%, bright par-
ticles at the dermal–epidermal junction, and plump
bright cells and collagen bundles were each found in
25–37% of cases.
The presence of peppering or the presence of plump
bright cells was more frequently found in BRAFp.V600E
mutated primary melanoma compared with wild-type
BRAF primary melanoma, being present, respectively,
in 63% of BRAFp.V600E mutated primary melanoma
cases and in 37% of wild-type BRAF primary
melanoma cases.
Discussion
Our study and its preliminary findings highlight for the
first time the hypothesis that RCM can detect specific
image patterns that can help distinguish different sub-
types of mutated melanomas, with a focus on the most
common BRAFV600E mutation. Histology is the gold
standard for the diagnosis of melanocytic tumors.
However, RCM is an important noninvasive diagnostic
tool that has enabled satisfactory characterization of
melanocytic and nonmelanocytic skin lesions. Numerous
articles describe its utility in defining cell population and
morphology in melanomas, which makes it a useful
supplement to clinical and histologic findings, with which
RCM shows precise correlates [10–14]. In addition,
interestingly, it was used for the follow-up of changing
moles in patients receiving treatment with BRAF inhi-
bitors for metastatic melanomas [15]. Remarkable results
were also achieved in the search for distinctive RCM
patterns in patients with multiple melanomas harboring
CDKN2A and MC1R variants [16], pointing to the
immense potential of in-vivo and noninvasive diagnostic
tools, and in particular RCM, in the study of the cellular
and architectural patterns of melanocytic lesions and their
genetic signature.
Moreover, the study underlines the ability of RCM to
evaluate the main morphologic patterns in melanomas
with BRAFV600E mutations, and also in the cases where
dermoscopy does not identify them. In particular,
regression patterns were also detected in those melan-
omas that at the first dermoscopic evaluation showed an
absence of dermoscopic peppering related to regression,
which was found in histology. Regression patterns are
represented by fibrosis (i.e. bright and thickened hyper-
refractive collagen fibers) and diffuse melanophages in
the dermis. Such cells are observed in RCM as irregularly
shaped and ill-defined plump bright cells, larger than
melanocytes, and with no visible nuclei. We assume that
the increased number of melanophages and initial organ-
ization of collagen fibers become visible before regres-
sion is consistent enough to create dermoscopic pepper-
ing so that RCM provides an earlier and more precise
characterization of melanoma features.
RCM can be an effective addition to dermoscopy, and
can be used in further characterization of less common
BRAF mutations such as V600K and V600R, which might
share specific dermoscopic patterns compared with more
frequent V600E1 [8,17,18]; in addition, NRAS and C-KIT
mutated melanomas should be investigated for their
imaging features.
Despite the small sample size, the authors believe that
their first steps and preliminary findings may provide
new insights into the characterization of malignant mel-
anomas to promptly screen patients who require genetic
testing. We confirm once again that RCM provides
additional and more specific information on the
cytoarchitectural structure of mutated melanomas com-
pared with dermoscopy. For example, it is interesting
that the semiquantitative evaluation of regression phe-
nomenon can be performed by RCM through the
numeric evaluation of plump bright cells and the
assessment of fibrosis, and also in cases in which der-
moscopic peppering is not clearly visible. The pathologist
and the confocalist can therefore cooperate in a more
precise overall assessment of tumor features. Of course,
further studies are needed to clarify the role of RCM and
other noninvasive diagnostic tools in the representation
of morphologic and genetic patterns of melanoma, to-
gether with further histologic correlations.
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